Literature DB >> 31278654

Bariatric Surgery Outcomes in Patients on Preoperative Therapeutic Anticoagulation: an Analysis of the 2015 to 2017 MBSAQIP.

Aryan Modasi1, Jerry T Dang2, Sadaf Afraz3, Joshua Hefler2, Noah Switzer2, Daniel W Birch4, Shahzeer Karmali4.   

Abstract

BACKGROUND: Obesity has been found to be an independent predictor of adverse cardiac and pulmonary embolic events. As the popularity of bariatric surgery grows, surgeons are encountering more patients taking therapeutic anticoagulation medications preoperatively. This study aims to assess the safety of bariatric surgery on these patients.
METHODS: Data was extracted from 2015 to 2017 using the MBSAQIP database. Included patients were those who underwent a primary LSG or LRYGB. A multivariable regression analysis was performed looking at 30-day outcomes for pre-operatively anticoagulated patients. A secondary propensity-matched analysis was performed comparing outcomes among patients undergoing LSG vs LRYGB.
RESULTS: A total of 430,396 patients were analyzed, 11,013 (2.56%) of which were taking anticoagulation medications pre-operatively. Absolute 30-day complication rates (8.73% vs 3.36%, p < 0.001), bleed rates (3.78% vs 0.88%, p < 0.001), leak rates (0.55% vs 0.41%, p = 0.021), cardiac event rates (0.43% vs 0.06%, p < 0.001), and venous thromboembolism rates (0.68% vs 0.25%, p < 0.001) were significantly higher among pre-operatively anticoagulated patients. On multivariable analysis, pre-operative anticoagulation was found to be an independent predictor of postoperative bleeding (OR 2.76, CI 2.43-3.14, p < 0.001) and mortality (OR 2.08, CI 1.49-2.90, p < 0.001). The LRYGB was associated with a significantly higher complication rate compared to the LSG (13.27% vs 7.40%, p < 0.001) in the propensity-matched cohorts.
CONCLUSIONS: Patients undergoing bariatric surgery on anticoagulation medications pre-operatively are at a significantly higher risk of adverse outcomes post-operatively. Patients who require long-term anticoagulation should undergo careful consideration before proceeding with bariatric surgery.

Entities:  

Keywords:  Anticoagulation; Bariatric surgery; Bariatrics; MBSAQIP; Obesity

Mesh:

Substances:

Year:  2019        PMID: 31278654     DOI: 10.1007/s11695-019-04064-3

Source DB:  PubMed          Journal:  Obes Surg        ISSN: 0960-8923            Impact factor:   4.129


  9 in total

1.  Is laparoscopic sleeve gastrectomy safer than laparoscopic gastric bypass? a comparison of 30-day complications using the MBSAQIP data registry.

Authors:  Sandhya B Kumar; Barbara C Hamilton; Stephanie G Wood; Stanley J Rogers; Jonathan T Carter; Matthew Y Lin
Journal:  Surg Obes Relat Dis       Date:  2018-02-08       Impact factor: 4.734

Review 2.  Principle mechanisms underlying venous thromboembolism: epidemiology, risk factors, pathophysiology and pathogenesis.

Authors:  Claus Kroegel; Angelika Reissig
Journal:  Respiration       Date:  2003 Jan-Feb       Impact factor: 3.580

3.  Bariatric Surgery in Patients on Chronic Anticoagulation Therapy.

Authors:  Gautam Sharma; Zubaidah Nor Hanipah; Ali Aminian; Suriya Punchai; Emre Bucak; Philip R Schauer; Stacy A Brethauer
Journal:  Obes Surg       Date:  2018-08       Impact factor: 4.129

4.  Obesity measures and risk of venous thromboembolism and myocardial infarction.

Authors:  Lars D Horvei; Sigrid K Brækkan; Ellisiv B Mathiesen; Inger Njølstad; Tom Wilsgaard; John-Bjarne Hansen
Journal:  Eur J Epidemiol       Date:  2014-09-12       Impact factor: 8.082

5.  Predicting venous thromboembolism following laparoscopic bariatric surgery: development of the BariClot tool using the MBSAQIP database.

Authors:  Jerry T Dang; Noah Switzer; Megan Delisle; Michael Laffin; Richdeep Gill; Daniel W Birch; Shahzeer Karmali
Journal:  Surg Endosc       Date:  2018-07-12       Impact factor: 4.584

6.  Assessment of the procoagulant potential after laparoscopic sleeve gastrectomy: a potential role for extended thromboprophylaxis.

Authors:  Amihai Rottenstreich; Ram Elazary; Jonathan B Yuval; Galia Spectre; Geffen Kleinstern; Yosef Kalish
Journal:  Surg Obes Relat Dis       Date:  2017-09-28       Impact factor: 4.734

7.  Warfarin users prone to coagulopathy in first 30 days after hospital discharge from gastric bypass.

Authors:  Peter Bechtel; Richard Boorse; Peter Rovito; T Daniel Harrison; John Hong
Journal:  Obes Surg       Date:  2013-10       Impact factor: 4.129

8.  Hemorrhagic and thromboembolic complications after bariatric surgery in patients receiving chronic anticoagulation therapy.

Authors:  Ramon Mourelo; Orit Kaidar-Person; Patricio Fajnwaks; Paul E Roa; David Pinto; Samuel Szomstein; Raul J Rosenthal
Journal:  Obes Surg       Date:  2008-01-05       Impact factor: 4.129

9.  Obesity, metabolic syndrome and risk of atrial fibrillation: a Swedish, prospective cohort study.

Authors:  Petter K Nyström; Axel C Carlsson; Karin Leander; Ulf de Faire; Mai-Lis Hellenius; Bruna Gigante
Journal:  PLoS One       Date:  2015-05-15       Impact factor: 3.240

  9 in total
  4 in total

1.  Development of the "OS-SEV90 Score" to Predict Severe Postoperative Complications at 90 Days Following Bariatric Surgery.

Authors:  Hugo Meunier; Benjamin Menahem; Yannick Le Roux; Adrien Lee Bion; Yoann Marion; Antoine Vallois; Nicolas Contival; Thomas Gautier; Jean Lubrano; Anaïs Briant; Jean-Jacques Parienti; Arnaud Alves
Journal:  Obes Surg       Date:  2021-04-28       Impact factor: 4.129

2.  Comment on: The APB study: apixaban pharmacokinetics in bariatric patients before to 1 year after vertical sleeve gastrectomy or Roux-en-Y gastric bypass.

Authors:  Jacqueline A Murtha; David A Harris; Luke M Funk
Journal:  Surg Obes Relat Dis       Date:  2022-01-31       Impact factor: 3.709

Review 3.  Missing something? A scoping review of venous thromboembolic events and their associations with bariatric surgery. Refining the evidence base.

Authors:  Walid El Ansari; Kareem El-Ansari
Journal:  Ann Med Surg (Lond)       Date:  2020-08-17

4.  Early Bleeding After Laparoscopic Roux-en-Y Gastric Bypass: Incidence, Risk Factors, and Management - a 21-Year Experience.

Authors:  Maja Odovic; Daniel Clerc; Nicolas Demartines; Michel Suter
Journal:  Obes Surg       Date:  2022-08-06       Impact factor: 3.479

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.